Review
Immunology
Suheil Albert Atallah-Yunes, Michael J. Robertson, Utpal P. Dave, Paola Ghione, Fabiana Perna
Summary: The prognosis for patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have shown promising results, but there is a need for further development of novel therapies to improve outcomes for non-responsive or relapsed patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Maria Huguet, Jose-Tomas Navarro, Jose Molto, Josep-Maria Ribera, Gustavo Tapia
Summary: Non-Hodgkin lymphoma (NHL) is a common HIV-related neoplasm, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. DLBCL in people with HIV presents with aggressive characteristics. The introduction of combined antiretroviral therapy (cART) and the use of cART with chemotherapy have significantly improved the prognosis for people with HIV and DLBCL, approaching that of the general population.
Review
Medicine, General & Internal
Eva Gonzalez Barca
Summary: This article describes new promising therapies that are in clinical development to treat relapsed/refractory DLBCL, including CAR T-cell and monoclonal antibody therapies.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Stefano Poletto, Mattia Novo, Luca Paruzzo, Pio Manlio Mirko Frascione, Umberto Vitolo
Summary: Diffuse large B-cell lymphoma (DLBCL) is a curable disease but a significant proportion of patients are unresponsive or relapse. New treatment options such as CAR-T have shown promising results for relapsed/refractory DLBCL. Efforts to improve frontline treatment have not been successful so far. Preliminary data on personalized therapy based on different molecular subtypes of DLBCL are encouraging.
CANCER TREATMENT REVIEWS
(2022)
Article
Medicine, General & Internal
Eric S. Geanes, Stacey A. Krepel, Rebecca McLennan, Stephen Pierce, Santosh Khanal, Todd Bradley
Summary: The study shows that bispecific antibodies targeting CD74 and IL4R on the surface of lymphoma cells could provide improved defense against rituximab resistance.
FRONTIERS IN MEDICINE
(2022)
Review
Hematology
Eliza A. Hawkes, Allison Barraclough, Laurie H. Sehn
Summary: Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, has a good prognosis in limited-stage DLBCL (LS-DLBCL) patients. Recent studies have provided new insights and strategies for the treatment of LS-DLBCL, including the use of PET scans and clinical trials. However, there is currently no standard definition for LS-DLBCL, and treatment strategies vary across studies, posing challenges in interpretation.
Article
Oncology
Jinrong Zhao, Yan Zhang, Wei Wang, Wei Zhang, Daobin Zhou
Summary: Pneumonia is a major life-threatening complication after chemotherapy in patients with DLBCL, and risk factors include pulmonary involvement, higher Eastern Cooperative Oncology Group score, and hypoalbuminemia. Researchers have developed a prediction model based on these factors, which can aid in the development of individualized strategies for preventing and treating post-chemotherapy pneumonia in DLBCL patients.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Prokop Vodicka, Pavel Klener, Marek Trneny
Summary: Genetic alterations in lymphoma cells serve as the basis for targeted therapy, but further research and clinical trials are needed to improve the survival rates of high-risk subsets of patients.
ONCOTARGETS AND THERAPY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lars Kurch, Andreas Huettmann, Thomas W. Georgi, Jan Rekowski, Osama Sabri, Christine Schmitz, Regine Kluge, Ulrich Duehrsen, Dirk Hasenclever
Summary: In diffuse large B-cell lymphoma, continuous scales such as qPET and Delta SUVmax are more suitable for predicting treatment outcomes based on interim PET scans compared to the ordinal Deauville scale. The positive predictive value curves for qPET and Delta SUVmax were found to be similar, with both methods identifying less than 15% of patients as poor responders. The study suggests that continuous scales offer more accurate outcome predictions in this context.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Jennifer M. Logue, Julio C. Chavez
Summary: Post CAR-T failures in R/R LBCL present a new unmet need with very poor prognosis. Standard treatment options are lacking, although FDA-approved medications like polatuzumab, tafasitamab, selinexor, and loncastuximab tesirine are available, data in this setting is limited. Clinical trials with bi-specific antibodies show encouraging results with manageable toxicities, suggesting their potential in this scenario. Additional cell therapies like dual CAR-T or allogeneic products may also be considered, but challenges with logistics and further immunosuppression need to be addressed. Consolidation with stem cell transplantation could be an option for eligible patients.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Review
Oncology
Natalia Yanguas-Casas, Lucia Pedrosa, Ismael Fernandez-Miranda, Margarita Sanchez-Beato
Summary: Lymphoma research integrates basic and applied research, providing insights for targeted therapies and personalized medicine through genomics studies on DLBCL. The genetic complexity and epigenetic alterations make precision medicine challenging for lymphoma patients, requiring further research to improve treatment options.
Review
Immunology
Eva Gonzalez Barca
Summary: Diffuse large B-cell lymphoma is an aggressive and biologically heterogeneous disease. Standard first-line therapy is R-CHOP, while salvage high-dose chemotherapy with autologous stem cell transplant is the standard second-line treatment. However, not all patients are eligible for these treatments, and IgG-like bispecific antibodies (BsAbs) have shown promising efficacy in B-cell lymphomas by targeting CD20 on B cells and engaging T cells via CD3. BsAbs have a favorable toxicity profile and are being studied in new trials to confirm their efficacy and explore their use in different lines of therapy or in combination with other drugs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Andrea Patriarca, Gianluca Gaidano
Summary: Understanding the molecular pathogenesis of DLBCL has led to the identification of potential druggable pathways and novel therapeutic targets such as small molecules, monoclonal and bispecific antibodies, drug-immunoconjugates, and cellular therapies. A precision medicine approach based on molecular predictors is desired for the development of investigational drugs for DLBCL. The optimal sequencing and use of emerging DLBCL drugs in different patient populations is important for personalized treatment strategies.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Oncology
Colton Ladbury, Swetha Kambhampati, Tamer Othman, Claire Hao, Lu Chen, Jeffrey Wong, Thai Cao, Alex Herrera, Matthew Mei, Savita Dandapani
Summary: Approximately 50% of patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) will relapse post-autologous stem cell transplant (ASCT). This study investigated the use of radiation therapy (RT) as salvage treatment for these patients. The results showed favorable oncologic outcomes for patients who received RT as first salvage therapy post-ASCT, particularly those with localized disease.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Cell Biology
Eva A. M. Hesius, Lidia van Laar, Margriet Oosterveld, Annemiek B. van Spriel, Blanca Scheijen, Jan Willem Leeuwis, Henri A. M. Marres, Patricia J. T. A. Groenen, Wendy B. C. Stevens, Ellen van Der Spek, Adriaan J. C. van den Brule, Brigiet M. Hoevenaars, Konnie M. Hebeda, Michiel van den Brand
Summary: LBCL-IRF4 is a newly identified subtype of large B cell lymphoma in the 2017 revised WHO classification, initially reported in children. This study aimed to assess the frequency of IRF4 rearrangements in adult DLBCLs that need to be reclassified as LBCL-IRF4 using FISH. Among 238 DLBCL patients, six (including the index patient) were found to have IRF4 rearrangements, and their immunohistochemical profile was consistent with LBCL-IRF4. This study highlights the importance of considering LBCL-IRF4 in older patients and at different anatomical sites.
Article
Hematology
Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski
Summary: By analyzing clinical characteristics, treatment, and clinical outcomes of MCL patients enrolled in a prospective cohort study, this study identified changes in frontline treatment patterns over the past years and found that these changes were associated with improved outcomes for patients.
Article
Hematology
Nicholas Borcherding, Kevin J. Severson, Nicholas Henderson, Luana S. Ortolan, Allison C. Rosenthal, Andrew M. Bellizzi, Vincent Liu, Brian K. Link, Aaron R. Mangold, Ali Jabbari
Summary: Cutaneous T-cell lymphomas (CTCLs) are a group of diseases caused by skin-tropic T-cell proliferation. The course of the disease varies, with some patients having indolent progression while others experience aggressive progression and poor survival. S e ' zary syndrome (SS), a leukemic variant of CTCL, lacks consistent markers for diagnosis and treatment selection. A study using single-cell sequencing identified distinct cell populations in SS and potential mechanisms of immune evasion.
Article
Oncology
Christopher S. S. Strouse, Melissa C. C. Larson, Shawna L. L. Ehlers, Kathleen J. J. Yost, Matthew J. J. Maurer, Stephen M. M. Ansell, David J. J. Inwards, Patrick B. B. Johnston, Ivana N. N. Micallef, Brian K. K. Link, Umar Farooq, James R. R. Cerhan, Carrie A. A. Thompson
Summary: This study assessed the long-term quality of life of patients with aggressive lymphoma subtypes treated with autologous hematopoietic cell transplant compared with those without history of transplant. The results showed that patients remaining in remission at 3 and 6 years after diagnosis had a high level of quality of life, with no significant differences associated with history of treatment with autologous hematopoietic cell transplant.
JCO ONCOLOGY PRACTICE
(2022)
Article
Hematology
Aung M. Tun, Arushi Khurana, Raphael Mwangi, Brian K. Link, Yucai Wang, Andrew L. Feldman, Carrie A. Thompson, Anne J. Novak, Jose C. Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S. Nowakowski, Thomas E. Witzig, Stephen M. Ansell, Lisa M. Rimsza, James R. Cerhan, Matthew J. Maurer, Thomas M. Habermann
Summary: This study found that the most common cause of death in patients with low-grade B-cell lymphomas in the first decade after diagnosis was not lymphoma-related. Early progression or retreatment events were strong predictors for the risk of lymphoma-related death.
Review
Hematology
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn
Summary: Comparative effectiveness studies using real-world data can provide complementary evidence on treatment effectiveness. By balancing baseline covariates using propensity score methods, closely matched patient-level cohorts can be generated for robust comparative analyses.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Evandro D. Bezerra, Madiha Iqbal, Javier Munoz, Arushi Khurana, Yucai Wang, Matthew J. Maurer, Radhika Bansal, Matthew A. Hathcock, Nora Bennani, Hemant S. Murthy, Allison C. Rosenthal, Jonas Paludo, Jose C. Villasboas, Patrick B. Johnston, Thomas M. Habermann, Stephen M. Ansell, Januario E. Castro, Thomas E. Witzig, Mohamed A. Kharfan-Dabaja, Grzegorz S. Nowakowski, Yi Lin
Article
Oncology
Angie Mae Rodday, Susan K. K. Parsons, Jenica N. N. Upshaw, Jonathan W. W. Friedberg, Andrea Gallamini, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K. K. Link, Eric Mou, Kerry J. J. Savage, Pier Luigi Zinzani, Matthew Maurer, Andrew M. M. Evens
Summary: A modern clinical prediction model was developed and validated to improve the prediction of prognosis in patients with advanced-stage classical Hodgkin lymphoma. The model was developed using data from eight international clinical trials and validated using data from real-world registries. Several important predictor variables were identified and an online calculator was created for individualized prediction.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Narendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey Danilov, Natalie S. Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I. Park, David A. Bond, Mehdi Hamadani, Timothy S. Fenske, Peter Martin, Mary-Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Brian K. Link, Lawrence D. Kaplan, David J. Inwards, Andrew L. Feldman, Eric D. Hsi, Kami Maddocks, Kristie A. Blum, Nancy L. Bartlett, James R. Cerhan, John P. Leonard, Thomas M. Habermann, Matthew J. Maurer, Jonathon B. Cohen
Summary: The study aims to evaluate the impact of diagnosis to treatment interval (DTI) on prognosis in newly diagnosed mantle cell lymphoma (MCL) patients. It was found that patients with short DTI had worse prognosis and were associated with adverse clinical factors and poor outcomes. Therefore, DTI should be considered and selection bias should be avoided in the treatment of MCL patients.
Article
Oncology
Melissa A. Hopper, Kerstin Wenzl, Keenan T. Hartert, Jordan E. Krull, Abigail R. Dropik, Joseph P. Novak, Michelle K. Manske, MaKayla R. Serres, Vivekananda Sarangi, Melissa C. Larson, Matthew J. Maurer, Zhi-Zhang Yang, Jonas Paludo, Ellen D. McPhail, Thomas M. Habermann, Brian K. Link, Lisa M. Rimsza, Stephen M. Ansell, James R. Cerhan, Dragan Jevremovic, Anne J. Novak
Summary: Non-follicular low-grade B-cell lymphomas (LGBCL) are biologically diverse entities that are difficult to categorize pathologically. By using RNA sequencing and machine learning approaches, this study identified five clusters of patients that were independent of subtype. One cluster had inferior outcome, upregulated cell cycle genes, and increased tumor immune cell content.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Summary: This study evaluated the efficacy and toxicity of Brexucabtagene autoleucel (brexu-cel) for relapsed/refractory mantle cell lymphoma (MCL) in the standard-of-care setting. The results showed that the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Cristina Correia, Matthew J. J. Maurer, Samantha J. J. McDonough, Paula A. A. Schneider, Paige E. E. Ross, Anne J. J. Novak, Andrew L. L. Feldman, James R. R. Cerhan, Susan L. L. Slager, Thomas E. E. Witzig, Bruce W. W. Eckloff, Hu Li, Grzegorz S. S. Nowakowski, Scott H. H. Kaufmann
Summary: The identification of follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. In a study on newly diagnosed FLs, BCL2 mutations with high variant allele frequency (VAF) were found to be associated with increased transformation risk and shorter event-free survival. However, other sequenced genes did not contribute significantly to the prognostic value of the panel. Nonsynonymous BCL2 mutations with VAF = 20% were consistently associated with decreased event-free survival and overall survival.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Diego Villa, Aixiang Jiang, Carlo Visco, Nicola Crosbie, Rory Mcculloch, Michael J. Buege, Anita Kumar, David A. Bond, Jonas Paludo, Matthew J. Maurer, Gita Thanarajasingam, Katharine L. Lewis, Chan Y. Cheah, Joachim Baech, Tarec C. El-Galaly, Laveniya Kugathasan, David W. Scott, Alina S. Gerrie, David Lewis
Summary: This study evaluated the prognostic factors in patients with relapsed/refractory mantle cell lymphoma (MCL) exclusively initiating second-line Bruton's tyrosine kinase inhibitors (BTKis) after first-line rituximab-containing therapy. The results showed that time to progression of disease (POD), Ki67, and MCL International Prognostic Index (MIPI) were associated with survival outcomes in patients receiving second-line BTKis. The study also developed web/application-based calculators to predict progression-free survival and overall survival in this population.
Article
Oncology
Zhi-Zhang Yang, Hyo Jin Kim, Hongyan Wu, Xinyi Tang, Yue Yu, Jordan Krull, Daniel P. Larson, Raymond M. Moore, Matthew J. Maurer, Kevin D. Pavelko, Shahrzad Jalali, Joshua C. Pritchett, Rekha Mudappathi, Junwen Wang, Jose C. Villasboas, Patrizia Mondello, Anne J. Novak, Stephen M. Ansell
Summary: T-lymphocytes in the tumor microenvironment of follicular lymphoma (FL) show diverse phenotypes, which may influence tumor biology and patient survival. Our analysis of 82 FL patients revealed four immune subgroups with different T-cell phenotypes, and a higher prevalence of CD57(+) T-FH cells with a late-stage differentiation phenotype was associated with poor patient survival.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea N. Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Ariela Noy, Wyndham H. Wilson, Mark Roschewski
Article
Hematology
Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers Em Patten, Bastian von Tresckow, Sonali M. Smith, Ana Isabel Jiminez Ubieto, Keith L. Davis, Saurabh P. Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link
Summary: This study aimed to construct a historical control cohort for relapsed/refractory follicular lymphoma (r/r FL) in order to enhance single-arm trials. The findings demonstrate the clinical characteristics and treatment outcomes of r/r FL patients, as well as the treatment limitations and unmet needs for certain patients. By comparing with previous studies, this research provides valuable control data for comparative studies.